We wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Friday, 13th February, 2026, has, inter alia, considered and approved the unaudited standalone ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Shentracon Chemicals approved unaudited standalone financial results for the quarter and nine months ended 31 December 2025, along with a clean (unqualified) limited review report from auditor MARK & Co. The company reported zero revenue from operations across all periods, with total income for Q3 FY26 at nil compared to ₹9.72 lakh in Q3 FY25. The company posted a small net loss of ₹(0.82) lakh in Q3 FY26, reversing a profit of ₹4.43 lakh in Q3 FY25. For the nine-month period, the net loss widened sharply to ₹(42.08) lakh from ₹(2.93) lakh in 9M FY25, driven by a ₹47.20 lakh exceptional item recorded in Q2. EPS for 9M FY26 stood at ₹(0.95) versus ₹(0.07) in the prior year period. The company has no operating segments, no subsidiaries, and paid-up equity capital of ₹443.81 lakh.
With zero revenue from operations and deepening losses amplified by a large exceptional item, shareholders should view this as a deeply concerning signal of business inactivity. The stock is likely to face negative sentiment given the lack of operational traction and continued erosion of shareholder value.